Management of ICI-associated toxicities in older adults with cancer: Recommendations from the SIOG
A recent article authored by Colm Mac Eochagain and colleagues was published in The Lancet Oncology.
Authors: Colm Mac Eochagain et al.
Immune checkpoint inhibitors (ICIs) have changed the treatment of numerous malignancies, offering significant advancements in cancer care.
Managing immune checkpoint inhibitor (ICI)-associated toxicities in older adults with cancer requires a careful and individualized approach. Aging brings changes in immune function, increases the likelihood of comorbidities, and often involves multiple medications, all of which can complicate the use of ICIs.
In this Policy Review by the International Society of Geriatric Oncology (SIOG), Colm Mac Eochagain and colleagues provide an evidence-based framework for health-care providers, caregivers, and policymakers. Their recommendations address the unique needs of older adults receiving ICIs, incorporating geriatric oncology principles that are often overlooked in existing guidelines.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023